Abatacept

How it works

Benefits

Dosage & preparation

Risks & contraindications

Highlighted claims

• Abatacept inhibits T cell activation by binding CD80 and CD86 on antigen-presenting cells. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
• Abatacept reduced rheumatoid arthritis progression compared with hydroxychloroquine in the trial. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
• In the primary modified full analysis set, 7 of 34 abatacept-treated participants developed rheumatoid arthritis during 24 months. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
• Abatacept is administered in this study as subcutaneous treatment for two years, weekly in year one and every two weeks in year two. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
• Time-to-event analysis favored abatacept, with a hazard ratio of 0.27 for progression to rheumatoid arthritis. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
• Abatacept was well tolerated during the two-year trial. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial